333 related articles for article (PubMed ID: 28416420)
1. Identification of Endogenous Biomarkers to Predict the Propensity of Drug Candidates to Cause Hepatic or Renal Transporter-Mediated Drug-Drug Interactions.
Chu X; Chan GH; Evers R
J Pharm Sci; 2017 Sep; 106(9):2357-2367. PubMed ID: 28416420
[TBL] [Abstract][Full Text] [Related]
2. Role of Hepatic Drug Transporters in Drug Development.
Liu H; Sahi J
J Clin Pharmacol; 2016 Jul; 56 Suppl 7():S11-22. PubMed ID: 27385168
[TBL] [Abstract][Full Text] [Related]
3. Prediction of pharmacokinetics and drug-drug interactions when hepatic transporters are involved.
Li R; Barton HA; Varma MV
Clin Pharmacokinet; 2014 Aug; 53(8):659-78. PubMed ID: 25056496
[TBL] [Abstract][Full Text] [Related]
4. Renal transporters in drug disposition, drug-drug interactions, and nephrotoxicity.
Feng B; El-Kattan AF; Radi ZA
Curr Protoc Toxicol; 2012 Aug; Chapter 23():Unit 23.3.1-15. PubMed ID: 22896010
[TBL] [Abstract][Full Text] [Related]
5. In vitro and in vivo approaches to characterize transporter-mediated disposition in drug discovery.
Feng B; Varma MV; Costales C; Zhang H; Tremaine L
Expert Opin Drug Discov; 2014 Aug; 9(8):873-90. PubMed ID: 24857286
[TBL] [Abstract][Full Text] [Related]
6. Transporter-Enzyme Interplay: Deconvoluting Effects of Hepatic Transporters and Enzymes on Drug Disposition Using Static and Dynamic Mechanistic Models.
Varma MV; El-Kattan AF
J Clin Pharmacol; 2016 Jul; 56 Suppl 7():S99-S109. PubMed ID: 27385183
[TBL] [Abstract][Full Text] [Related]
7. Biomarkers for In Vivo Assessment of Transporter Function.
Müller F; Sharma A; König J; Fromm MF
Pharmacol Rev; 2018 Apr; 70(2):246-277. PubMed ID: 29487084
[TBL] [Abstract][Full Text] [Related]
8. Evaluation and Quantitative Prediction of Renal Transporter-Mediated Drug-Drug Interactions.
Feng B; Varma MV
J Clin Pharmacol; 2016 Jul; 56 Suppl 7():S110-21. PubMed ID: 27385169
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of drug-drug interaction in the hepatobiliary and renal transport of drugs.
Shitara Y; Sato H; Sugiyama Y
Annu Rev Pharmacol Toxicol; 2005; 45():689-723. PubMed ID: 15822193
[TBL] [Abstract][Full Text] [Related]
10. Development of novel, 384-well high-throughput assay panels for human drug transporters: drug interaction and safety assessment in support of discovery research.
Tang H; Shen DR; Han YH; Kong Y; Balimane P; Marino A; Gao M; Wu S; Xie D; Soars MG; O'Connell JC; Rodrigues AD; Zhang L; Cvijic ME
J Biomol Screen; 2013 Oct; 18(9):1072-83. PubMed ID: 24062352
[TBL] [Abstract][Full Text] [Related]
11. Endogenous Biomarkers to Assess Drug-Drug Interactions by Drug Transporters and Enzymes.
Mariappan TT; Shen H; Marathe P
Curr Drug Metab; 2017 Oct; 18(8):757-768. PubMed ID: 28738769
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of New Chemical Entities as Substrates of Liver Transporters in the Pharmaceutical Industry: Response to Regulatory Requirements and Future Steps.
Okudaira N
J Pharm Sci; 2017 Sep; 106(9):2251-2256. PubMed ID: 28533120
[TBL] [Abstract][Full Text] [Related]
13. Current progress in identifying endogenous biomarker candidates for drug transporter phenotyping and their potential application to drug development.
Mochizuki T; Mizuno T; Maeda K; Kusuhara H
Drug Metab Pharmacokinet; 2021 Apr; 37():100358. PubMed ID: 33461054
[TBL] [Abstract][Full Text] [Related]
14. Use of PET Imaging to Evaluate Transporter-Mediated Drug-Drug Interactions.
Langer O
J Clin Pharmacol; 2016 Jul; 56 Suppl 7():S143-56. PubMed ID: 27385172
[TBL] [Abstract][Full Text] [Related]
15. Use of in vitro transporter assays to understand hepatic and renal disposition of new drug candidates.
Sahi J
Expert Opin Drug Metab Toxicol; 2005 Oct; 1(3):409-27. PubMed ID: 16863453
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of cynomolgus monkeys for the identification of endogenous biomarkers for hepatic transporter inhibition and as a translatable model to predict pharmacokinetic interactions with statins in humans.
Chu X; Shih SJ; Shaw R; Hentze H; Chan GH; Owens K; Wang S; Cai X; Newton D; Castro-Perez J; Salituro G; Palamanda J; Fernandis A; Ng CK; Liaw A; Savage MJ; Evers R
Drug Metab Dispos; 2015 Jun; 43(6):851-63. PubMed ID: 25813937
[TBL] [Abstract][Full Text] [Related]
17. Transporter-mediated tissue targeting of therapeutic molecules in drug discovery.
Zhou J; Xu J; Huang Z; Wang M
Bioorg Med Chem Lett; 2015 Mar; 25(5):993-7. PubMed ID: 25650254
[TBL] [Abstract][Full Text] [Related]
18. Hepatic drug transporters: the journey so far.
Riley RJ; Foley SA; Barton P; Soars MG; Williamson B
Expert Opin Drug Metab Toxicol; 2016; 12(2):201-16. PubMed ID: 26670591
[TBL] [Abstract][Full Text] [Related]
19. Renal clearance in drug discovery and development: molecular descriptors, drug transporters and disease state.
Feng B; LaPerle JL; Chang G; Varma MV
Expert Opin Drug Metab Toxicol; 2010 Aug; 6(8):939-52. PubMed ID: 20433402
[TBL] [Abstract][Full Text] [Related]
20. Importance of Hepatic Transporters in Clinical Disposition of Drugs and Their Metabolites.
Patel M; Taskar KS; Zamek-Gliszczynski MJ
J Clin Pharmacol; 2016 Jul; 56 Suppl 7():S23-39. PubMed ID: 27385177
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
